Phase II Study Comparing Consolidation with <sup>90</sup>Y Ibritumomab Tiuxetan to Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma


Phase II Study Comparing Consolidation with 90Y Ibritumomab Tiuxetan to Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Lopez-Guillermo A et al. A randomized Phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan (Zevalin®) (Z) vs maintenance with rituximab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R-CHOP. Preliminary results at 36 months from randomization. Proc ASH 2013;Abstract 369.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.